SHANGHAI – Hutchison China Meditech Ltd. (Chi-Med) and its partner, Astrazeneca plc, of London, shared phase II safety and efficacy data for savolitinib in patients with papillary renal cell carcinoma (PRCC), a fatal form of kidney cancer.